JP4989224B2 - Ｄｎａワクチン組成物およびその使用方法 - Google Patents
Ｄｎａワクチン組成物およびその使用方法 Download PDFInfo
- Publication number
- JP4989224B2 JP4989224B2 JP2006527060A JP2006527060A JP4989224B2 JP 4989224 B2 JP4989224 B2 JP 4989224B2 JP 2006527060 A JP2006527060 A JP 2006527060A JP 2006527060 A JP2006527060 A JP 2006527060A JP 4989224 B2 JP4989224 B2 JP 4989224B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- hiv
- gene
- vaccine
- ltr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 9
- 108010041986 DNA Vaccines Proteins 0.000 title description 38
- 229940021995 DNA vaccine Drugs 0.000 title description 38
- 238000000034 method Methods 0.000 title description 5
- 108020004414 DNA Proteins 0.000 claims description 76
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 21
- 230000003612 virological effect Effects 0.000 claims description 13
- 230000008488 polyadenylation Effects 0.000 claims description 12
- 102000053602 DNA Human genes 0.000 claims description 10
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 8
- 108700026220 vif Genes Proteins 0.000 claims description 8
- 108700004026 gag Genes Proteins 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 108010061833 Integrases Proteins 0.000 claims description 6
- 101150098622 gag gene Proteins 0.000 claims description 4
- 108700026222 vpu Genes Proteins 0.000 claims description 4
- 101150040614 vpx gene Proteins 0.000 claims description 4
- 108700004025 env Genes Proteins 0.000 claims description 3
- 101150059999 pro gene Proteins 0.000 claims description 3
- 101150090490 vpu gene Proteins 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims 3
- 102100034343 Integrase Human genes 0.000 claims 2
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 claims 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 101150030339 env gene Proteins 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 108700004030 rev Genes Proteins 0.000 claims 1
- 101150098213 rev gene Proteins 0.000 claims 1
- 108700026215 vpr Genes Proteins 0.000 claims 1
- 101150024249 vpr gene Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 61
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 40
- 241000700605 Viruses Species 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 17
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 15
- 108010067390 Viral Proteins Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 102100034349 Integrase Human genes 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 208000031886 HIV Infections Diseases 0.000 description 11
- 241000282553 Macaca Species 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 230000036039 immunity Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 108020005202 Viral DNA Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108700004028 nef Genes Proteins 0.000 description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 230000007969 cellular immunity Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 101710201961 Virion infectivity factor Proteins 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 101150059019 vif gene Proteins 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102400001093 PAK-2p27 Human genes 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 101150104269 RT gene Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 108700004029 pol Genes Proteins 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 244000052613 viral pathogen Species 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000245063 Primula Species 0.000 description 2
- 235000016311 Primula vulgaris Nutrition 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 101150023385 nef gene Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000012124 AIDS-related disease Diseases 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010049076 End stage AIDS Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 101150062334 int gene Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000007486 viral budding Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50319703P | 2003-09-16 | 2003-09-16 | |
| US60/503,197 | 2003-09-16 | ||
| US10/941,164 US7488485B2 (en) | 2003-09-16 | 2004-09-15 | DNA vaccine compositions and methods of use |
| US10/941,164 | 2004-09-15 | ||
| PCT/US2004/030512 WO2005027844A2 (en) | 2003-09-16 | 2004-09-16 | Dna vaccine compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505923A JP2007505923A (ja) | 2007-03-15 |
| JP2007505923A5 JP2007505923A5 (enExample) | 2011-01-20 |
| JP4989224B2 true JP4989224B2 (ja) | 2012-08-01 |
Family
ID=34381064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527060A Expired - Fee Related JP4989224B2 (ja) | 2003-09-16 | 2004-09-16 | Ｄｎａワクチン組成物およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7488485B2 (enExample) |
| EP (1) | EP1667523B1 (enExample) |
| JP (1) | JP4989224B2 (enExample) |
| AU (1) | AU2004273965B2 (enExample) |
| BR (1) | BRPI0414442A (enExample) |
| CA (1) | CA2538840C (enExample) |
| DK (1) | DK1667523T3 (enExample) |
| ES (1) | ES2399875T3 (enExample) |
| IL (1) | IL174325A (enExample) |
| NZ (1) | NZ545954A (enExample) |
| PL (1) | PL1667523T3 (enExample) |
| PT (1) | PT1667523E (enExample) |
| WO (1) | WO2005027844A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7488485B2 (en) * | 2003-09-16 | 2009-02-10 | University Of Kansas Medical Center | DNA vaccine compositions and methods of use |
| US8765140B2 (en) * | 2003-09-16 | 2014-07-01 | University Of Kansas Medical Center | DNA vaccine compositions with HIV/SIV gene modifications |
| PT1880008E (pt) * | 2005-05-03 | 2015-08-27 | Inserm Inst Nat De La Santé Et De La Rech Médicale | Expressão de proteína mitocondrial através de uma abordagem alotópica melhorada |
| US7585675B2 (en) * | 2005-11-15 | 2009-09-08 | University Of Kansas Medical Center | Inhibition of HIV and SHIV replication with antisense interleukin-4 |
| FR2979919B1 (fr) * | 2011-09-12 | 2015-12-11 | Centre Nat Rech Scient | Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1 |
| WO2013126469A1 (en) * | 2012-02-21 | 2013-08-29 | Immunogenetix Therapeutics, Inc. | Chimeric dna vaccine compositions and methods of use |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| KR20230131481A (ko) | 2021-01-14 | 2023-09-13 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신 및 이의 사용 방법 |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| US6531123B1 (en) * | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
| US7488485B2 (en) * | 2003-09-16 | 2009-02-10 | University Of Kansas Medical Center | DNA vaccine compositions and methods of use |
| US7122180B2 (en) * | 2000-10-23 | 2006-10-17 | Children's Medical Center Corporation | DNA vectors containing mutated HIV proviruses |
-
2004
- 2004-09-15 US US10/941,164 patent/US7488485B2/en not_active Expired - Fee Related
- 2004-09-16 PT PT4784389T patent/PT1667523E/pt unknown
- 2004-09-16 JP JP2006527060A patent/JP4989224B2/ja not_active Expired - Fee Related
- 2004-09-16 WO PCT/US2004/030512 patent/WO2005027844A2/en not_active Ceased
- 2004-09-16 ES ES04784389T patent/ES2399875T3/es not_active Expired - Lifetime
- 2004-09-16 EP EP04784389A patent/EP1667523B1/en not_active Expired - Lifetime
- 2004-09-16 CA CA2538840A patent/CA2538840C/en not_active Expired - Fee Related
- 2004-09-16 DK DK04784389.1T patent/DK1667523T3/da active
- 2004-09-16 NZ NZ545954A patent/NZ545954A/en not_active IP Right Cessation
- 2004-09-16 AU AU2004273965A patent/AU2004273965B2/en not_active Ceased
- 2004-09-16 PL PL04784389T patent/PL1667523T3/pl unknown
- 2004-09-16 BR BRPI0414442-2A patent/BRPI0414442A/pt active Search and Examination
-
2006
- 2006-03-15 IL IL174325A patent/IL174325A/en not_active IP Right Cessation
-
2009
- 2009-02-09 US US12/368,151 patent/US8003113B2/en not_active Expired - Fee Related
-
2011
- 2011-07-18 US US13/185,164 patent/US8916174B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1667523B1 (en) | 2012-11-21 |
| US8916174B2 (en) | 2014-12-23 |
| US20090233857A1 (en) | 2009-09-17 |
| AU2004273965A1 (en) | 2005-03-31 |
| PT1667523E (pt) | 2013-02-04 |
| AU2004273965B2 (en) | 2010-12-09 |
| JP2007505923A (ja) | 2007-03-15 |
| WO2005027844A3 (en) | 2005-10-06 |
| ES2399875T3 (es) | 2013-04-04 |
| DK1667523T3 (da) | 2013-01-21 |
| EP1667523A2 (en) | 2006-06-14 |
| WO2005027844A2 (en) | 2005-03-31 |
| US8003113B2 (en) | 2011-08-23 |
| US20120207782A1 (en) | 2012-08-16 |
| PL1667523T3 (pl) | 2013-05-31 |
| CA2538840A1 (en) | 2005-03-31 |
| NZ545954A (en) | 2009-04-30 |
| IL174325A (en) | 2015-07-30 |
| US20050112102A1 (en) | 2005-05-26 |
| EP1667523A4 (en) | 2007-12-19 |
| CA2538840C (en) | 2014-02-18 |
| IL174325A0 (en) | 2008-04-13 |
| BRPI0414442A (pt) | 2006-11-14 |
| US7488485B2 (en) | 2009-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8916174B2 (en) | HIV DNA vaccine regulated by a caev-derived promoter | |
| KR100996330B1 (ko) | Ｈｉｖ 조절/부속 단백질의 융합 단백질 | |
| JPWO2012053646A1 (ja) | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター | |
| ES2282041B1 (es) | Mejoras introducidas en el objeto de la patente principal n es200501841 para "vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida". | |
| Rabinovich et al. | A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice | |
| US8765140B2 (en) | DNA vaccine compositions with HIV/SIV gene modifications | |
| Warren | Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates | |
| WO2013026452A1 (en) | Method for removing immunosuppresive properties of hiv envelope glycoproteins | |
| Lecollinet et al. | Vaccination against the feline immunodeficiency virus: the road not taken | |
| JP2010530356A (ja) | 急性伝染ｈｉｖエンベロープ・サイン | |
| Singh et al. | HIV vaccine development | |
| ZA200603044B (en) | DNA vaccine compositions and methods of use | |
| MXPA06002993A (en) | Dna vaccine compositions and methods of use | |
| US20170107260A1 (en) | Mosaic hiv-1 sequences and uses thereof | |
| US20070010471A1 (en) | HIV DNA vaccine | |
| McGettigan et al. | HIV-1 vaccines: the search continues | |
| JP2024509976A (ja) | 抗原をｍｈｃ－ｉｉ経路にターゲティングし、宿主におけるｃｄ８＋及びｃｄ４＋ｔ細胞による防御免疫を誘導するレンチウイルスベクター | |
| Norley et al. | Vaccine development using the simian immunodeficiency virus model for AIDS | |
| Jesil et al. | HIV VACCI ES: PRESE T SCE ARIO AD FUTURE PROSPECTS | |
| Hallengärd | Improving the immunogenicity of HIV-1 DNA vaccines. | |
| Busch | Evaluation of different SIV plasmid DNA vaccines: A model for HIV vaccine development | |
| Hostel | Efficacy and their Delivery System: A Review | |
| HK1076822B (en) | Fusion protein of hiv regulatory/accessory proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070913 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20101129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110705 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110928 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120105 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120403 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120427 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |